Published in Blood on September 22, 2005
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res (2008) 3.57
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med (2008) 2.46
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood (2006) 2.36
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Regulatory T cells and treatment of cancer. Curr Opin Immunol (2008) 2.01
Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res (2006) 1.58
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood (2007) 1.47
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Signaling defects in anti-tumor T cells. Immunol Rev (2008) 1.28
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol (2008) 1.26
Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest (2009) 1.17
Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron (2012) 1.15
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol (2014) 1.14
Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res (2010) 1.14
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood (2005) 1.13
Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res (2009) 1.13
Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res (2009) 1.11
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell response. J Immunol (2006) 1.09
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol (2012) 1.09
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood (2008) 1.07
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood (2010) 1.03
Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol (2009) 1.02
Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res (2009) 1.01
Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther (2011) 1.00
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol (2012) 0.99
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood (2007) 0.97
B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol (2012) 0.97
Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology (2012) 0.92
Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. J Immunol (2011) 0.92
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91
How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol (2013) 0.91
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant (2008) 0.89
T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol (2010) 0.89
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling. Breast Cancer Res Treat (2013) 0.89
Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation. J Immunol (2011) 0.88
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells. PLoS One (2010) 0.87
Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol (2013) 0.86
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv Exp Med Biol (2009) 0.85
Immunotherapy for metastatic prostate cancer. Urol Oncol (2007) 0.85
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol (2013) 0.84
Immune response in thyroid cancer: widening the boundaries. Scientifica (Cairo) (2014) 0.84
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer (2014) 0.84
Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J Immunol (2009) 0.84
Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin Exp Immunol (2008) 0.84
An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther (2009) 0.84
Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther (2009) 0.83
Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells. Cancer Immunol Immunother (2010) 0.81
Conditioning of naive CD4(+) T cells for enhanced peripheral Foxp3 induction by nonspecific bystander inflammation. Nat Immunol (2016) 0.81
Chemoimmunotherapy as long-term maintenance therapy for cancer. Oncoimmunology (2012) 0.80
Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS One (2014) 0.79
The roles of antigen-specificity, responsiveness to transforming growth factor-β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells. Immunology (2010) 0.78
Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes. Oncoimmunology (2013) 0.78
The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention. Acta Biochim Biophys Sin (Shanghai) (2015) 0.77
Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo. PLoS One (2012) 0.76
Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells. Neural Regen Res (2012) 0.76
Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration. ISRN Oncol (2013) 0.76
Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. J Biomed Biotechnol (2010) 0.76
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget (2015) 0.76
TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer. Oncotarget (2016) 0.75
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci (2017) 0.75
Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines (Basel) (2016) 0.75
Regulatory considerations for clinical development of cancer vaccines. Hum Vaccin Immunother (2014) 0.75
Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10. Br J Cancer (2010) 0.75
Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management. Hum Vaccin Immunother (2016) 0.75
Interleukin 21 inhibits cancer-mediated FOXP3 induction in naïve human CD4 T cells. Cancer Immunol Immunother (2017) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol (2003) 19.16
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature (1997) 16.28
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Regulatory T cells in autoimmmunity*. Annu Rev Immunol (2000) 9.36
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Origin of regulatory T cells with known specificity for antigen. Nat Immunol (2002) 7.49
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med (2003) 5.23
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science (2002) 4.21
In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A (2003) 4.18
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 3.81
Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev (2001) 3.31
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med (1980) 3.17
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
'Educated' dendritic cells act as messengers from memory to naive T helper cells. Nat Immunol (2004) 1.96
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol (2002) 1.88
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun (2002) 1.80
Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol (2004) 1.63
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol (2002) 1.55
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A (1999) 1.48
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother (2002) 1.25
Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog (1996) 1.09
CD25+ regulatory T cells and tumor immunity. Immunol Lett (2003) 0.94
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res (2008) 3.09
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A (2008) 2.20
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood (2010) 1.99
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res (2011) 1.97
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92
B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol (2005) 1.78
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A (2004) 1.63
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol (2011) 1.58
Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res (2003) 1.56
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One (2012) 1.52
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res (2009) 1.49
Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 1.45
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol (2015) 1.45
Parabolic resection for mitral valve repair. Interact Cardiovasc Thorac Surg (2009) 1.39
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 1.39
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res (2011) 1.38
LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med (2004) 1.32
Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol (2011) 1.28
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol (2004) 1.21
CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol (2003) 1.19
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 1.17
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res (2010) 1.15
Characterization of chronic myeloid leukemia stem cells. Am J Hematol (2011) 1.15
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur J Immunol (2010) 1.09
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07
Current status of immunological therapies for prostate cancer. Curr Opin Urol (2010) 1.06
STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol (2009) 1.06
Allogeneic versus autologous blood transfusion and survival after radical prostatectomy. Transfusion (2014) 1.00
Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies. Cancer Causes Control (2010) 0.99
Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription. J Immunol (2006) 0.98
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood (2007) 0.97
Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol (2009) 0.96
Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev (2012) 0.94
Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med (2009) 0.94
Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response. J Immunol (2011) 0.94
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol (2012) 0.92
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int (2013) 0.90
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant (2008) 0.89
Immune signatures predict prognosis in localized cancer. Cancer Invest (2010) 0.88
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol (2009) 0.87
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) (2015) 0.85
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83
Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. J Urol (2006) 0.82
Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther (2009) 0.82
Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines. Int J Cancer (2002) 0.82
Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate (2011) 0.81
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys (2013) 0.81
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Immunol Cell Biol (2011) 0.80
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more. Oncoimmunology (2012) 0.78
Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) (2014) 0.78
TE-array--a high throughput tool to study transposon transcription. BMC Genomics (2013) 0.77
Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. Prostate (2012) 0.77
Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res (2007) 0.77
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs (2014) 0.76
Personalized Immune Therapy: A Slippery Fish? Oncology (Williston Park) (2016) 0.75
Current immunotherapeutic strategies in prostate cancer. Surg Oncol Clin N Am (2007) 0.75
Combination immunotherapy in renal cell carcinoma. Clin Adv Hematol Oncol (2016) 0.75
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. Am J Surg Pathol (2017) 0.75